PMID- 19563027
OWN - NLM
STAT- MEDLINE
DCOM- 20100527
LR  - 20171116
IS  - 0253-2727 (Print)
IS  - 0253-2727 (Linking)
VI  - 30
IP  - 1
DP  - 2009 Jan
TI  - [Lipoprotein lipase and serum thymidine kinase level in chronic lymphocytic 
      leukemia and their correlations with other prognostic factors].
PG  - 8-12
AB  - OBJECTIVE: To investigate lipoprotein lipase (LPL) and serum thymidine kinase 
      (TK) levels in chronic lymphocytic leukemia (CLL) and their correlations with 
      other prognostic factors. METHODS: LPL expression level in peripheral blood 
      samples of 58 CLL patients was detected by semi-quantitative reverse 
      transcription PCR (RT-PCR). Serum TK1 level in 39 CLL patients was detected by 
      enhanced chemiluminescence (ECL) and TK monoclonal antibody (Anti-TK mAb). IgVH 
      mutation status was detected by multiplex PCR and sequencing of purified PCR 
      products. The expression of ZAP-70 protein and CD38 were determined by flow 
      cytometry . Panel probes and fluorescence in situ hybridization (FISH) were used 
      to detect cytogenetic aberrations. RESULTS: The median LPL expression level in 
      CLL was 0.26 (0 -6.29), while undetectable in normal controls. LPL expression 
      level was significantly correlated with IgVH mutation status, Binet stages, CD38 
      and cytogenetic aberrations. Patients with unmutated IgVH genes had higher LPL 
      than those with IgVH mutations (P = 0.010). Patients in Binet stage B and C had 
      higher LPL than those in stage A (P = 0.011). LPL level was higher in patients 
      with CD38 > or = 30% (P = 0.001). Higher LPL level was found in patients with 
      unfavorable cytogenetic aberrations (deletion in 17p13 or 11q22) than those with 
      favorable cytogenetics (deletion in 13q as the sole abnormality) (P = 0.002). LPL 
      level was not significantly correlated with sex, age, and ZAP-70 protein (P > 
      0.05). The level of TK1 was higher in CLL patients than that in normal control (P 
      < 0.05). Patients with higher level of absolute lymphocyte count (ALC), lactate 
      dehydrogenase (LDH), unmutated IgVH genes and ZAP-70 had higher levels of TK1 
      than those with lower level of ALC, LDH, mutated IgVH genes and ZAP-70 (P = 
      0.018, P = 0.018, P = 0.030 and P = 0.038, respectively). TK1 level had no 
      correlation with sex, age, Binet stages, CD38, and cytogenetic aberrations (P > 
      0.05). CONCLUSIONS: LPL expression and serum TK1 levels significantly correlate 
      with other CLL prognostic factors and could be predictive markers for IgVH 
      mutation status. LPL and serum TK1 might be applied to the assessment of 
      prognosis in CLL patients.
FAU - Xu, Wei
AU  - Xu W
AD  - Department of Hematology, First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China.
FAU - Shen, Qiu-Dan
AU  - Shen QD
FAU - Yu, Hui
AU  - Yu H
FAU - Qiao, Chun
AU  - Qiao C
FAU - Wu, Yu-Jie
AU  - Wu YJ
FAU - Liu, Qiong
AU  - Liu Q
FAU - Zhu, Dan-Xia
AU  - Zhu DX
FAU - Miao, Kou-Rong
AU  - Miao KR
FAU - Li, Jian-Yong
AU  - Li JY
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 0 (Immunoglobulin Heavy Chains)
RN  - EC 2.7.1.21 (Thymidine Kinase)
RN  - EC 2.7.1.21 (thymidine kinase 1)
RN  - EC 2.7.10.2 (ZAP-70 Protein-Tyrosine Kinase)
RN  - EC 3.1.1.34 (Lipoprotein Lipase)
RN  - EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
SB  - IM
MH  - ADP-ribosyl Cyclase 1/metabolism
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Humans
MH  - Immunoglobulin Heavy Chains/genetics
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*enzymology/metabolism
MH  - Lipoprotein Lipase/*blood
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Thymidine Kinase/*blood
MH  - ZAP-70 Protein-Tyrosine Kinase/metabolism
EDAT- 2009/07/01 09:00
MHDA- 2010/05/28 06:00
CRDT- 2009/07/01 09:00
PHST- 2009/07/01 09:00 [entrez]
PHST- 2009/07/01 09:00 [pubmed]
PHST- 2010/05/28 06:00 [medline]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2009 Jan;30(1):8-12.